𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

✍ Scribed by Eveline Boucher; Hervé Jouanolle; Patrice Andre; Annick Ruffault; Dominique Guyader; Romain Moirand; Bruno Turlin; Christian Jacquelinet; Pierre Brissot; Yves Deugnier

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
744 KB
Volume
21
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase lev-TOLOGY 199% 21 :322-327.

📜 SIMILAR VOLUMES

A randomized controlled trial of high-do
A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C
✍ Di Marco, Vito; Lo Iacono, Oreste; Cammà, Calogero; Almasio, Piero L.; Vaccaro, 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

In chronic hepatitis C virus (HCV) infection, the rate of sustained response to interferon is low. We evaluated, in patients responding to a 26-week course of interferon, the effect of high-dose maintenance therapy in preventing relapse. Three hundred and ten patients with chronic HCV infection (38.

Ability of prolonged interferon treatmen
Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial
✍ Akinori Kasahara; Norio Hayashi; Naoki Hiramatsu; Masahide Oshita; Hideki Hagiwa 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 882 KB

The aim of this study was to determine whether 12 months course of interferon alfa (IFN-a) therapy could improve the beneficial effect of IFN in chronic hepatitis C. Eighty-eight patients were treated with natural IFNa for either 28 weeks (45 cases) or 52 weeks (43 cases). Sustained response was ach

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Sequential versus concomitant administra
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
✍ Raffaello Sostegni; Valeria Ghisetti; Fabrizia Pittaluga; Giovanna Marchiaro; Gi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

We conducted a three-arm, randomized trial in 96 patients with chronic hepatitis C who did not respond to interferon alfa to compare treatments. Group 1 (33 patients) received ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n-3 alone (3 MU thrice weekly for 6 months); group

Randomized trial of high-dose interferon
Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy
✍ Nami Mori; Michio Imamura; Yoshiiku Kawakami; Hiromi Saneto; Tomokazu Kawaoka; S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 1 views

## Abstract The aim of this study was to compare the efficacy of high‐dose interferon (IFN)‐α‐2b with standard dose of IFN‐α‐2b in combination with ribavirin (RBV) for patients with chronic hepatitis C virus (HCV) infection, and to investigate the predictive factors associated with virological resp

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission